Navigation Links
Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
Date:2/26/2008

TSX: BMR

TORONTO, Feb. 26 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Phase II data on the Company's Neuradiab product candidate as a treatment for newly diagnosed glioblastoma multiforme (GBM) were published in the journal, Neuro-Oncology. (http://neuro-oncology.dukejournals.org/cgi/rapidpdf/15228517-2007-053v1) This report summarizes the most recent clinical results utilizing patient-specific dosing of Neuradiab (I-131 mAb81c6) as an adjunctive therapy to oral chemotherapy, surgery and external beam radiation in patients with newly diagnosed GBM.

The study, conducted at Duke University Medical Center evaluating the efficacy and toxicity of Neuradiab as an adjunct to standard of care therapy in a 21 patient trial, demonstrated a 42 percent increase in overall survival compared to a historical control of the current standard of care. The article titled, "A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost", written by David A. Reardon and Michael R. Zalutsky as lead authors, will be published in the April 2008 edition of Neuro-Oncology.

"This article represents a detailed review of the results from the patient-specific dosing protocol utilized in the Neuradiab Phase II trial. The study forms the basis for the design of our multi-center Phase III trial. We are pleased to have the results published and look forward to working with Dr. David Reardon as the principal investigator and our extensive base of investigators and thought leaders as we approach the start of our multi-center trial," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "The article outlines the potential benefit of patient-specific dosing wi
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer Medical Isotope Supply For Phase III Trial Secure
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... 2014 Join the more than 80 golfers ... Center’s first ever charity golf tournament to benefit Project HEAL, ... disorders who cannot afford treatment. The tournament will be held ... Mo. , The day-long event starts with 10:30 a.m. ... award dinner will begin at 5 p.m. and will include ...
(Date:10/1/2014)... October 01, 2014 Diet Doc understands that ... to lose weight and their dieting attempts could be easily ... Including hormone diet treatments into their programs as ... to see fast and effective weight loss results, it also ... healthy habits to maintain their weight for the future. , ...
(Date:10/1/2014)... Bahir Dar, Ethiopia, at the occasion of the ... some 150 African and international leishmaniasis experts, results ... and efficacy monitoring plan, carried out by ... Uganda, and Ethiopia, were presented to key decision ... treatment of kala-azar with the combination of Sodium ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... simple diagnostic modality can help predict the outcome of ... It can predict which patient would benefit from the ... valuable study can be found in the latest issue ... physicians identify factors that cause specific symptoms by demonstrating ...
... prescription drugs in the filtered and recycled wastewater at ... dangerous effects this water might have in the future. ... antibiotics, antipsychotics, birth-control hormones, Viagra and Valium have been ... the wastewater is because people flush them down their ...
... Boston, a surgery was conducted on a baby inside the womb. ... the womb. // She was discharged on Friday after the successful ... a heart defect called hypoplastic left heart syndrome (HLHS) inside the ... in the developing fetus on November 7, 2005. ,She ...
... services in a hospital at Brisbane a patient had to ... was attacked and was in serious condition, attention could not ... Caboolture Hospital, where emergency services are scarce due to shortage ... presently operational from 8am to 6pm every day. ...
... announced that it intends to fast track its inhaled insulin ... Food and Drug Administration // and the European Commission ... Sanofi-Aventis and Nektar Therapeutics. ,It is a relatively ... or syringes are needed. "Until today, patients with diabetes who ...
... successfully reached the Vinson Massif summit, one of Antarctica's ... and was successfully completed on January 19th after eight ... was a strong, healthy athlete who was later diagnosed ... of the disease he lost 80 pounds and his ...
Cached Medicine News:Health News:SPECT Can Help Predict Treatment Outcome In Patients With Low Back Pain 2Health News:Medications Detected In Recycled Water In Los Angeles 2Health News:Baby Underwent A Heart Surgery Inside The Womb 2Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
(Date:9/30/2014)... 30, 2014  Hologic, Inc. (NASDAQ: HOLX ... President and Chief Executive Officer, will preside over the ... the first day of Breast Cancer Awareness Month. In ... focused on the important benefits of Hologic,s 3D Mammography ... as clinically superior to traditional mammography. ...
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... , September 30, 2014 ... report the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, ... Kits, and Reagents], Application (Immunology, Oncology) & ... 2019", published by MarketsandMarkets, provides a detailed ... opportunities, current market trends, and strategies impacting ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... of researchers from Wake Forest University Baptist Medical Center is ... tiny nanoparticles and destroy tumors with the ensuing heat. , ... Today at the 52nd Annual Meeting ... , they will describe the latest development for this technology: iron-containing Multi-Walled ...
... July 21 Zargis Medical Corp., a majority-owned ... that it received a contract from the U.S. Army to ... Signal-X6™ telemedicine systems recently deployed to the Army under a ... will develop prototype versions of the Signal-X6 system that will ...
Cached Medicine Technology:Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors 2Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors 3Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors 4Zargis Awarded U.S. Army Contract 2Zargis Awarded U.S. Army Contract 3
With an intuitive operator interface, enhanced sample handling and innovative menu, the state-of-the-art Access 2 system delivers new levels of laboratory efficiency, standardization and cost effecti...
...
...
...
Medicine Products: